NASDAQ$ZURA
Zura Bio Limited · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Zura Bio reported Q2 2025, net loss of $16M.
For Q2 2025, Zura Bio reported a net loss of $16M. Management discusses operating trends, capital, and sector risks in the quarterly filing.
- Net loss $16M.
- Zura Bio MD&A highlights liquidity, capital, and core trends.
- Segment and macro factors shape year-over-year comparisons.
Headline financials
Revenue & EPS history
Zura Bio · Revenue · Quarterly
$0
Forward guidance
Clinical-stage and small biotech emphasize pipeline milestones and cash runway.
Tailwinds
- Clinical progress and partnerships.
- Regulatory pathway optionality.
- Balance-sheet flexibility.
Headwinds
- Operating losses and financing needs.
- Trial and regulatory risk.
- Commercialization timing uncertain.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q2 2025
-1.2%
Avg return
Earnings day
-2.4%
Avg return
5 days after
-3.1%
Avg return
30 days after
36%
4 / 11 earnings
Positive
+22.8%
Q4 2023
Best reaction
-26.0%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -3.2% | -2.9% | -30.5% | |
| Q4 2025 | -9.5% | -17.3% | -13.2% | |
| Q2 2025 | +6.9% | +8.8% | +25.8% | |
| Q1 2025 | -7.6% | -14.2% | +0.0% | |
| Q4 2024 | +4.0% | +5.3% | -33.0% | |
| Q1 2024 | -0.6% | +9.6% | -14.9% | |
| Q4 2023 | +22.8% | +26.3% | +90.1% | |
| Q3 2023 | +2.8% | -1.2% | -4.2% | |
| Q2 2023 | -0.6% | -1.2% | +1.8% | |
| Q1 2023 | -26.0% | -28.5% | -3.0% | |
| Q4 2022 | -1.8% | -11.4% | -52.5% | |
| Q3 2022 | — | — | — | |
| Q2 2022 | — | — | — | |
| Q1 2022 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro